$JRSS
JRSIS HEALTH CARE Corp Stock $jrss

$jrss Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000114420416133532 Filed on November 14, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q4
Revenue	$5.160M	$4.257M	$3.810M
YoY Change	35.43%	45.4%	145.81%
Cost Of Revenue	$1.510M	$1.162M	$1.010M
YoY Change	49.5%	38.87%	129.55%
Gross Profit	$3.650M	$3.095M	$2.800M
YoY Change	30.36%	48.02%	152.25%
Gross Profit Margin	70.74%	72.71%	73.49%
Selling, General & Admin	$800.0K	$760.0K	$630.0K
YoY Change	26.98%	52.0%	50.0%
% of Gross Profit	21.92%	24.55%	22.5%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$300.0K	$282.3K	$240.0K
YoY Change	25.0%	22.42%	242.86%
% of Gross Profit	8.22%	9.12%	8.57%
Operating Expenses	$1.960M	$1.590M	$1.420M
YoY Change	38.03%	35.9%	125.4%
Operating Profit	$1.690M	$1.171M	$1.380M
YoY Change	22.46%	95.0%	187.5%
Interest Expense	-$350.0K	$339.7K	-$340.0K
YoY Change	2.94%	7.46%	-2.86%
% of Operating Profit	-20.71%	29.02%	-24.64%
Other Income/Expense, Net	$0.00	-$857.00	$0.00
YoY Change		-74.73%	-100.0%
Pretax Income	$1.340M	$1.170M	$1.040M
YoY Change	28.85%	95.96%	642.86%
Income Tax	$0.00	$866.00	$0.00
% Of Pretax Income	0.0%	0.07%	0.0%
Net Earnings	$920.0K	$813.1K	$710.0K
YoY Change	29.58%	104.92%	787.5%
Net Earnings / Revenue	17.83%	19.1%	18.64%
Basic Earnings Per Share
Diluted Earnings Per Share	$55.09K	$48.50K	$42.54K
COMMON SHARES
Basic Shares Outstanding	13.92M shares	13.92M shares	13.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$890.0K	$600.0K	$350.0K
YoY Change	154.29%	27.66%	-66.67%
Cash & Equivalents	$890.7K	$597.0K	$352.2K
Short-Term Investments
Other Short-Term Assets	$580.0K	$540.0K	$260.0K
YoY Change	123.08%	315.38%	-66.67%
Inventory	$801.2K	$810.0K	$499.1K
Prepaid Expenses	$518.7K		$201.5K
Receivables	$3.336M	$2.400M	$2.009M
Other Receivables	$1.555K	$1.580M	$2.125K
Total Short-Term Assets	$7.418M	$5.930M	$4.208M
YoY Change	76.29%	117.22%	47.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.27M	$24.38M	$22.45M
YoY Change	3.68%	7.12%	10.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.010M	$1.070M	$1.080M
YoY Change	-6.48%	5.94%	58.82%
Total Long-Term Assets	$24.28M	$25.44M	$23.53M
YoY Change	3.22%	7.03%	11.99%
TOTAL ASSETS
Total Short-Term Assets	$7.418M	$5.930M	$4.208M
Total Long-Term Assets	$24.28M	$25.44M	$23.53M
Total Assets	$31.70M	$31.37M	$27.74M
YoY Change	14.3%	18.38%	16.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$743.7K	$910.0K	$352.8K
YoY Change	110.79%	160.0%	21.19%
Accrued Expenses	$50.00K	$50.00K	$40.00K
YoY Change	25.0%	25.0%	33.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$434.8K	$0.00
YoY Change		-14.75%	-100.0%
Long-Term Debt Due	$2.310M	$2.170M	$1.880M
YoY Change	22.87%	28.4%	132.1%
Total Short-Term Liabilities	$3.218M	$3.639M	$2.461M
YoY Change	30.77%	38.9%	-17.31%
LONG-TERM LIABILITIES
Long-Term Debt	$16.80M	$16.91M	$17.86M
YoY Change	-5.94%	-2.48%	12.33%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$16.80M	$16.91M	$17.86M
YoY Change	-5.94%	-2.48%	12.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.218M	$3.639M	$2.461M
Total Long-Term Liabilities	$16.80M	$16.91M	$17.86M
Total Liabilities	$20.02M	$20.55M	$20.32M
YoY Change	-1.52%	-12.16%	7.66%
SHAREHOLDERS EQUITY
Retained Earnings	$6.274M	$5.350M	$2.802M
YoY Change	123.9%		177.04%
Common Stock	$1.146M	$1.146M	$1.146M
YoY Change	0.0%		18.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.634M	$6.041M	$3.688M
YoY Change
Total Liabilities & Shareholders Equity	$31.70M	$31.37M	$27.74M
YoY Change	14.3%	18.39%	16.2%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q4
OPERATING ACTIVITIES
Net Income	$920.0K	$813.1K	$710.0K
YoY Change	29.58%	104.92%	787.5%
Depreciation, Depletion And Amortization	$300.0K	$282.3K	$240.0K
YoY Change	25.0%	22.42%	242.86%
Cash From Operating Activities	$1.080M	$490.0K	$1.100M
YoY Change	-1.82%	-43.68%	35.8%
INVESTING ACTIVITIES
Capital Expenditures	-$130.0K	-$480.0K	-$1.400M
YoY Change	-90.71%	-64.18%	2.94%
Acquisitions
YoY Change
Other Investing Activities	-$570.0K	$430.0K	$10.00K
YoY Change	-5800.0%	-23.21%	-75.0%
Cash From Investing Activities	-$690.0K	-$50.00K	-$1.390M
YoY Change	-50.36%	-93.59%	5.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-30.00K	-710.0K	350.0K
YoY Change	-108.57%	173.08%	-20.45%
NET CHANGE
Cash From Operating Activities	1.080M	490.0K	1.100M
Cash From Investing Activities	-690.0K	-50.00K	-1.390M
Cash From Financing Activities	-30.00K	-710.0K	350.0K
Net Change In Cash	360.0K	-270.0K	60.00K
YoY Change	500.0%	58.82%	-185.71%
FREE CASH FLOW
Cash From Operating Activities	$1.080M	$490.0K	$1.100M
Capital Expenditures	-$130.0K	-$480.0K	-$1.400M
Free Cash Flow	$1.210M	$970.0K	$2.500M
YoY Change	-51.6%	-56.11%	15.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	50311	USD
CY2016Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10820022	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7411545	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31374198	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-857	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3392	USD
CY2016Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	27126	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	118274	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.0288
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	445404	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	333473	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	68913	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-507	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	68086	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1427860	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	421331	USD
	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	0	USD
	us-gaap	Interest Expense Other InterestExpenseOther	903737	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-428106	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	75985	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2012Q4	jrss	Joint Venture Investment Obligation To Pay Capital JointVentureInvestmentObligationToPayCapital	5247203	USD
CY2013Q2	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.7	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25	pure
CY2016Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	2420195	USD
CY2015Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	2035271	USD
CY2016Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	25112	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26411776	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2032080	USD
	jrss	Consulting Fee ConsultingFee	51425	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2548115	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	JRSIS HEALTH CARE Corp
CY2016Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	434768	USD
CY2015Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2016Q3	us-gaap	Deposit Liability Current DepositLiabilityCurrent	5988	USD
CY2015Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	6666	USD
CY2016Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	34728	USD
CY2015Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	97328	USD
CY2016Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	26911	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	78307	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	44376	USD
CY2016Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	2174016	USD
CY2015Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	1881200	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3639305	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2460666	USD
CY2016Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	16307291	USD
CY2015Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	17863608	USD
CY2016Q3	us-gaap	Liabilities Liabilities	20554176	USD
CY2015Q4	us-gaap	Liabilities Liabilities	20324274	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	13915	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	13915	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1132423	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1132423	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	5350300	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2802184	USD
CY2016Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-455838	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-260669	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	6040800	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	3687853	USD
CY2016Q3	us-gaap	Minority Interest MinorityInterest	4779222	USD
CY2015Q4	us-gaap	Minority Interest MinorityInterest	3723692	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27735819	USD
CY2016Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	67641	USD
CY2015Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	63034	USD
CY2015Q4	us-gaap	Deferred Costs DeferredCosts	252138	USD
CY2016Q3	us-gaap	Deferred Costs DeferredCosts	188365	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1846898	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1388861	USD
CY2016Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	2410346	USD
CY2015Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	1539039	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	4257244	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	2927900	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1161959	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	836741	USD
CY2016Q3	jrss	Cost Of Medical Consumables CostOfMedicalConsumables	382891	USD
CY2015Q3	jrss	Cost Of Medical Consumables CostOfMedicalConsumables	239678	USD
CY2016Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	720860	USD
CY2015Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	491110	USD
CY2016Q3	us-gaap	Supplies Expense SuppliesExpense	70142	USD
CY2015Q3	us-gaap	Supplies Expense SuppliesExpense	136260	USD
CY2016Q3	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	17374	USD
CY2015Q3	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	9193	USD
CY2016Q3	us-gaap	Utilities Costs UtilitiesCosts	76027	USD
CY2015Q3	us-gaap	Utilities Costs UtilitiesCosts	62851	USD
CY2016Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	15868	USD
CY2015Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	0	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	339737	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	316151	USD
CY2016Q3	us-gaap	Professional Fees ProfessionalFees	19351	USD
CY2015Q3	us-gaap	Professional Fees ProfessionalFees	4929	USD
CY2016Q3	us-gaap	Depreciation Depreciation	282302	USD
CY2015Q3	us-gaap	Depreciation Depreciation	230606	USD
CY2016Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3086511	USD
CY2015Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2327519	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	600381	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1169876	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	596989	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	866	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	925	USD
CY2016Q3	us-gaap	Profit Loss ProfitLoss	1169010	USD
CY2015Q3	us-gaap	Profit Loss ProfitLoss	596064	USD
CY2016Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	355950	USD
CY2015Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	199293	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	813060	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	396771	USD
CY2016Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-11530	USD
CY2015Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-81019	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-566997	USD
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	65498	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	785934	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	207614	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13915000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13788872	shares
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.0584
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1170733	USD
	us-gaap	Interest Expense Other InterestExpenseOther	1030949	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	25802	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23745925	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1298014	USD
	jrss	Consulting Fee ConsultingFee	12764	USD
CY2016Q3	jrss	Consulting Fee ConsultingFee	16912	USD
CY2015Q3	jrss	Consulting Fee ConsultingFee	7923	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	2090976	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	1460508	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	13619479	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	18481307	USD
CY2016Q3	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	1310344	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	12481	USD
CY2015Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	189157	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1130354	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	325888	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	344420	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1042058	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1121548	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	3914023	USD
CY2015Q3	jrss	Capital Lease Financing Fees CapitalLeaseFinancingFees	325062	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	226848	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	446649	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	425795	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	303474	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-191282	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-1121619	USD
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	525	USD
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	6775	USD
CY2015Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	9265	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1082845	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3346535	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3753997	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2918429	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3141645	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	178048	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2149599	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1931772	USD
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	904854	USD
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	3849970	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-747429	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	986665	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-3296	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	152315	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	244869	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-574805	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1046485	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	471680	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3172	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1699	USD
	us-gaap	Interest Paid Net InterestPaidNet	1030949	USD
	us-gaap	Interest Paid Net InterestPaidNet	903737	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-1109581	USD
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	531897	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	45355	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	28030	USD
CY2016Q3	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.0609	pure
	us-gaap	Interest Expense Debt InterestExpenseDebt	19384	USD
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13915000	shares
	jrss	Capital Lease Financing Fees CapitalLeaseFinancingFees	1028871	USD
	jrss	Capital Lease Financing Fees CapitalLeaseFinancingFees	893883	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13915000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13915000	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13915000	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001597892
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	JRSS
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13915000	shares
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	0	USD
CY2015	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	0	USD
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	784140	USD
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	774296	USD
CY2012Q4	jrss	Joint Venture Investment Obligation To Pay Capital JointVentureInvestmentObligationToPayCapital	35000000	CNY
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <i><font style="FONT-SIZE: 10pt">C.</font></i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <i><font style="FONT-SIZE: 10pt">Use of estimates</font></i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of unaudited consolidated financial statements in conformity with U. S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q3	jrss	Capital Lease Financing Fees CapitalLeaseFinancingFees	349488	USD
CY2013Q2	jrss	Capital Leases Frequency Of Periodic Payment CapitalLeasesFrequencyOfPeriodicPayment	annual
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <i><font style="FONT-SIZE: 10pt">E.</font></i></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <i><font style="FONT-SIZE: 10pt">Concentration of Credit Risk</font></i></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the nine months ended September 30, 2016 and 2015, no customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of net revenue. As of September 30, 2016 and December 31, 2015, 2 and 1 customer accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	0	USD
CY2016Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	607580	USD

Files In Submission

Name	View Source	Status
0001144204-16-133532-index-headers.html	Edgar Link	pending
0001144204-16-133532-index.html	Edgar Link	pending
0001144204-16-133532.txt	Edgar Link	pending
0001144204-16-133532-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jrss-20160930.xml	Edgar Link	completed
jrss-20160930.xsd	Edgar Link	pending
jrss-20160930_cal.xml	Edgar Link	unprocessable
jrss-20160930_def.xml	Edgar Link	unprocessable
jrss-20160930_lab.xml	Edgar Link	unprocessable
jrss-20160930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v452361_10q.htm	Edgar Link	pending
v452361_ex31-1.htm	Edgar Link	pending
v452361_ex31-2.htm	Edgar Link	pending
v452361_ex32-1.htm	Edgar Link	pending
v452361_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JRSS
JRSIS HEALTH CARE Corp Stock $jrss

2016 Q4 Form 10-Q Financial Statement

#000114420416133532 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JRSS JRSIS HEALTH CARE Corp Stock $jrss

2016 Q4 Form 10-Q Financial Statement

#000114420416133532 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JRSS
JRSIS HEALTH CARE Corp Stock $jrss